ENGN — enGene Therapeutics Share Price
0.000.00%
Last trade - 00:00- $540.60m
- $289.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.92 | ||
| Price to Tang. Book | 1.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.03% | ||
| Return on Equity | -46.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 24.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Directors
- Last Annual
- October 31st, 2025
- Last Interim
- January 31st, 2026
- Incorporated
- October 31st, 2023
- Public Since
- December 10th, 2021
- No. of Shareholders
- 64
- No. of Employees
- 45
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 66,989,466
- Address
- 4868 Rue Levy, Suite 220, SAINT-LAURENT, H4R 2P1
- Web
- https://engene.com
- Phone
- +1 5143324888
- Auditors
- KPMG LLP
Upcoming Events for ENGN
Q2 2026 enGene Holdings Inc Earnings Release
enGene Holdings Inc Annual Shareholders Meeting
Q3 2026 enGene Holdings Inc Earnings Release
Similar to ENGN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the enGene Therapeutics share price?
As of Today at 20:29 UTC, shares in enGene Therapeutics are trading at $8.07. This share price information is delayed by 15 minutes.
How has the enGene Therapeutics share price performed this year?
Shares in enGene Therapeutics last closed at $8.07 and the price had moved by +101.75% over the past 365 days. In terms of relative price strength the enGene Therapeutics share price has outperformed the S&P500 Index by +46.04% over the past year.
What are the analyst and broker recommendations for enGene Therapeutics?
The overall consensus recommendation for enGene Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the enGene Therapeutics dividend yield?
enGene Therapeutics does not currently pay a dividend.
Does enGene Therapeutics pay a dividend?
enGene Therapeutics does not currently pay a dividend.
When does enGene Therapeutics next pay dividends?
enGene Therapeutics does not currently pay a dividend.
How do I buy enGene Therapeutics shares?
To buy shares in enGene Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of enGene Therapeutics?
As of the previous close price of $8.07, shares in enGene Therapeutics had a market capitalisation of $540.60m.
Where are enGene Therapeutics shares listed?
Here are the trading details for enGene Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENGN
What kind of share is enGene Therapeutics?
Based on an overall assessment of its quality, value and momentum enGene Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a enGene Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in enGene Therapeutics is $24.12. That is 198.88% above the last closing price of $8.07.
Analysts covering enGene Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.00 for the next financial year.
Find out moreWhat is the trend in the enGene Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like enGene Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -18.42%.
As of the last closing price of $8.07, shares in enGene Therapeutics were trading +12.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the enGene Therapeutics PE Ratio?
The enGene Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of enGene Therapeutics?
We do not have data on enGene Therapeutics' directors